/KRYS
KRYS Stock - Krystal Biotech, Inc.
Healthcare|BiotechnologyNASDAQ
$240.80+3.18%
+$7.43 (+3.18%) • Dec 19
68
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).36
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-7.0%upside
Target: $223.94
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for KRYS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$238.39 – $243.21
TARGET (TP)$224.00
STOP LOSS$221.54
RISK/REWARD1:-0.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.48
52W High$248.59
52W Low$122.80
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $290.51M | $50.70M | N/A | N/A | N/A |
| Gross Profit | $270.45M | $47.60M | N/A | N/A | $-1,851,000 |
| Gross Margin | 93.1% | 93.9% | N/A | N/A | N/A |
| Operating Income | $65.69M | $-109,727,000 | $-145,196,000 | $-68,275,000 | $-32,999,000 |
| Net Income | $89.16M | $10.93M | $-139,975,000 | $-69,570,000 | $-32,167,000 |
| Net Margin | 30.7% | 21.6% | N/A | N/A | N/A |
| EPS | $3.12 | $0.40 | $-5.49 | $-3.13 | $-1.71 |
Company Overview
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
75%
Hold / Neutral
2
25%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
6 Bullish2 Neutral/Bearish
Price Targets
$147
Average Target
↓ 39.0% Downside
Now
$74
Low
$147
Average
$245
High
Based on 9 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| March 5th 2025 | Jefferies | Initiation | Buy | $245 |
| August 6th 2024 | Citigroup | Downgrade | Neutral | $204← $195 |
| November 20th 2023 | Goldman | Initiation | Buy | $160 |
| October 24th 2023 | Cantor Fitzgerald | Initiation | Overweight | $100 |
| October 12th 2023 | Citigroup | Initiation | Buy | $160 |
| September 7th 2023 | Berenberg | Initiation | Buy | $154 |
| April 18th 2023 | Stifel | Initiation | Buy | $102 |
| February 28th 2023 | Goldman | Upgrade | Buy | $124← $79 |
| August 25th 2022 | Goldman | Downgrade | Neutral | $74 |
Earnings History & Surprises
KRYSBeat Rate
56%
Last 18 quarters
Avg Surprise
+8.0%
EPS vs Estimate
Beats / Misses
10/7
1 met exactly
Latest EPS
$2.66
Q4 2025
EPS Surprise History
Q1 24
+178.9%
$0.30vs$-0.38
Q2 24
-80.0%
$0.03vs$0.15
Q3 24
+72.0%
$0.86vs$0.50
Q4 24
+1.1%
$0.91vs$0.90
Q1 25
+17.8%
$1.52vs$1.29
Q2 25
-13.0%
$1.20vs$1.38
Q3 25
+19.4%
$1.29vs$1.08
Q4 25
+137.5%
$2.66vs$1.12
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 18, 2026 | $1.62 | — | — | — |
Q4 2025 | Nov 3, 2025 | $1.12 | $2.66 | +137.5% | ✓ BEAT |
Q3 2025 | Aug 4, 2025 | $1.08 | $1.29 | +19.4% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $1.38 | $1.20 | -13.0% | ✗ MISS |
Q1 2025 | Feb 19, 2025 | $1.29 | $1.52 | +17.8% | ✓ BEAT |
Q4 2024 | Nov 4, 2024 | $0.90 | $0.91 | +1.1% | ✓ BEAT |
Q3 2024 | Aug 5, 2024 | $0.50 | $0.86 | +72.0% | ✓ BEAT |
Q2 2024 | May 6, 2024 | $0.15 | $0.03 | -80.0% | ✗ MISS |
Q1 2024 | Feb 26, 2024 | $-0.38 | $0.30 | +178.9% | ✓ BEAT |
Q4 2023 | Nov 6, 2023 | $-1.10 | $-0.67 | +39.1% | ✓ BEAT |
Q3 2023 | Aug 7, 2023 | $-0.42 | $-1.25 | -197.6% | ✗ MISS |
Q2 2023 | May 8, 2023 | $-1.41 | $-1.76 | -24.8% | ✗ MISS |
Q1 2023 | Feb 27, 2023 | $-1.39 | $-1.25 | +10.1% | ✓ BEAT |
Q4 2022 | Nov 7, 2022 | $-1.23 | $-1.17 | +4.9% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-1.08 | $-1.10 | -1.9% | ✗ MISS |
Q2 2022 | May 9, 2022 | $-0.96 | $-0.99 | -3.1% | ✗ MISS |
Q1 2022 | Feb 28, 2022 | $-0.76 | $-0.94 | -23.7% | ✗ MISS |
Q4 2021 | Nov 8, 2021 | $-0.75 | $-0.70 | +6.7% | ✓ BEAT |
Q3 2021 | Aug 9, 2021 | $-0.74 | $-0.74 | 0.0% | = MET |
Latest News
Citigroup Maintains Neutral on Krystal Biotech, Raises Price Target to $198
➖ NeutralBenzinga•Nov 4, 2025, 06:02 PM•Also:
Krystal Biotech shares are trading higher after Chardan Capital raised its price target on the stock from $216 to $220.
📈 PositiveBenzinga•Nov 4, 2025, 04:07 PM
Chardan Capital Maintains Buy on Krystal Biotech, Raises Price Target to $220
📈 PositiveBenzinga•Nov 4, 2025, 01:23 PM
Krystal Biotech Q3 EPS $2.66 Beats $1.03 Estimate, Sales $97.800M Beat $93.186M Estimate
📈 PositiveBenzinga•Nov 3, 2025, 12:01 PM
Krystal Biotech Unit Launches VYJUVEK In Japan For Treatment Of Dystrophic Epidermolysis Bullosa; VYJUVEK Priced At ¥2,955,232.7 Per Unit In Japan
📈 PositiveBenzinga•Oct 22, 2025, 01:14 PM
B of A Securities Maintains Buy on Krystal Biotech, Raises Price Target to $255
📈 PositiveBenzinga•Oct 17, 2025, 11:02 AM
Krystal Biotech Says It Gets US FDA's Platform Technology Designation For HSV-1 Viral Vector To Treat Neurotrophic Keratitis
📈 PositiveBenzinga•Oct 14, 2025, 12:09 PM
HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $240 Price Target
📈 PositiveBenzinga•Sep 15, 2025, 06:31 PM
Krystal Biotech Announces FDA Approval For A Revised VYJUVEK Label Allowing Treatment Of DEB Patients From Birth
📈 PositiveBenzinga•Sep 15, 2025, 12:06 PM
HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $240 Price Target
📈 PositiveBenzinga•Aug 22, 2025, 10:39 AM
Krystal Biotech Granted An End Of Phase 2 Meeting With The FDA In October To Discuss Registration Path For Inhaled KB707 Following NSCLC Data
📈 PositiveBenzinga•Aug 21, 2025, 04:14 PM
Frequently Asked Questions about KRYS
What is KRYS's current stock price?
Krystal Biotech, Inc. (KRYS) is currently trading at $240.80 per share. The stock has moved +3.18% today.
What is the analyst price target for KRYS?
The average analyst price target for KRYS is $224.00, based on 1 analyst.
What sector is Krystal Biotech, Inc. in?
Krystal Biotech, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is KRYS's market cap?
Krystal Biotech, Inc. has a market capitalization of $6.98 billion, making it a mid-cap company.
Does KRYS pay dividends?
No, Krystal Biotech, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACLX
Arcellx, Inc.
$63.96
Mkt Cap: $3.5B
ALKS
Alkermes plc
$28.45
Mkt Cap: $4.7B
ARWR
Arrowhead Pharmaceuticals, Inc.
$68.16
Mkt Cap: $9.4B
CRSP
CRISPR Therapeutics AG
$55.86
Mkt Cap: $4.9B
MTSR
Metsera, Inc.
$70.50
Mkt Cap: $7.4B
PCVX
Vaxcyte, Inc.
$46.42
Mkt Cap: $6.1B
PTCT
PTC Therapeutics, Inc.
$78.57
Mkt Cap: $6.3B
PTGX
Protagonist Therapeutics, Inc.
$86.05
Mkt Cap: $5.4B
TFX
Teleflex Incorporated
$121.89
Mkt Cap: $5.4B
TGTX
TG Therapeutics, Inc.
$30.98
Mkt Cap: $4.9B
Explore stocks similar to KRYS for comparison